Inhibikase Therapeutics I... (IKT)
2.40
0.10 (4.35%)
At close: Mar 03, 2025, 12:22 PM
Inhibikase Therapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Cash & Equivalents | 9.17M | 7.19M | 40.75M | 13.95M | 18.46K | 379.56K | 16.66K | 12.04K |
| Short-Term Investments | 4.09M | 15.86M | n/a | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | -15.85M | n/a | n/a | n/a | n/a | 87.1K | n/a |
| Other Long-Term Assets | n/a | 15.85M | n/a | n/a | 2.87K | 1.59M | n/a | 82.76K |
| Receivables | n/a | 39.88K | 110.14K | n/a | n/a | 472.94K | 180.78K | 66.88K |
| Inventory | n/a | 1.12M | 107K | n/a | n/a | n/a | n/a | 0.00 |
| Other Current Assets | 959K | 1.28M | 1.61M | 829.19K | 16.92K | 399.09K | 625.00 | 1.25K |
| Total Current Assets | 14.21M | 24.37M | 42.47M | 14.78M | 35.38K | 1.25M | 198.07K | 80.16K |
| Property-Plant & Equipment | 295.6K | 565.17K | n/a | n/a | n/a | n/a | n/a | n/a |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 295.6K | 565.17K | n/a | n/a | 2.87K | 1.59M | 87.1K | 82.76K |
| Total Assets | 14.51M | 24.94M | 42.47M | 14.78M | 38.25K | 2.85M | 285.17K | 162.93K |
| Account Payables | 646.77K | 1.15M | 1.09M | 1.72M | 1M | 954.24K | 353.52K | 431.79K |
| Deferred Revenue | n/a | n/a | n/a | 2.33M | 1.43M | 262.37K | 5.64K | n/a |
| Short-Term Debt | 531.88K | 291.67K | 248.91K | 42.53K | 98.42K | 233.73K | 454.32K | 328.94K |
| Other Current Liabilities | 2.26M | 2.25M | 2.72M | 632.93K | 1.72M | 2.17M | 907.05K | 753.9K |
| Total Current Liabilities | 3.44M | 3.7M | 4.05M | 4.72M | 4.25M | 3.62M | 1.73M | 1.51M |
| Long-Term Debt | 90.12K | 205.45K | n/a | 276.46K | 275.38K | n/a | n/a | n/a |
| Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Liabilities | 90.12K | 205.45K | 2.72M | 276.46K | 275.38K | 1.45M | n/a | n/a |
| Total Liabilities | 3.53M | 3.9M | 4.05M | 5M | 4.53M | 3.62M | 1.73M | 1.51M |
| Total Debt | 622K | 351.29K | 248.91K | 319K | 373.79K | 233.73K | 459.96K | 328.94K |
| Common Stock | 6.19K | 25.23K | 25.16K | 10.05K | 8.18K | 8.18K | 8.92K | 8.92K |
| Retained Earnings | -66.9M | -47.87M | -29.82M | -15.03M | -12.18M | -6.46M | -4.31M | -3.87M |
| Comprehensive Income | 877.00 | 104.72K | -0.00 | 0.00 | n/a | n/a | n/a | n/a |
| Shareholders Equity | 10.98M | 21.04M | 38.42M | 9.78M | -4.49M | -777.97K | -1.44M | -1.35M |
| Total Investments | 4.09M | 15.86K | n/a | n/a | n/a | n/a | 87.1K | n/a |